Savara Inc. announced the online publication of a manuscript titled 'Long-Term Outcomes in Five Patients with Autoimmune Pulmonary Alveolar Proteinosis Treated with Molgramostim Inhalation Solution' in the journal ERJ Open Research. This publication provides additional data supporting the efficacy of its lead program.
The outcomes data suggest that treatment with molgramostim addresses the underlying pathophysiology of aPAP, leading to improved lung function, decreased disease burden, restored patient functionality, and a reduction of clinical symptoms. Patients in the case series, who received molgramostim for a mean duration of 4.2 years, showed improvements in pulmonary gas transfer and activities of daily living.
Furthermore, the data indicated a reduction in surfactant burden and a decreased need for whole lung lavage procedures after more than one year on treatment. No serious adverse events were reported, and treatment was well tolerated, reinforcing the drug's safety profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.